Fabry Disease – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Fabry Disease – Drugs In Development, 2024 report and make more profitable business decisions.
Fabry disease is an X-linked lysosomal disorder that results in abnormal deposits of globotriaosylceramide in blood vessel walls throughout the body. It is caused by mutations in the GLA gene. The GLA gene controls the production of a particular enzyme called alpha-galactosidase A, which is responsible for breaking down globotriaosylceramide. Symptoms include skin rash, cramps, gas, diarrhea, heart enlargement, angina, dizziness, headache, nausea, and heat intolerance. Treatment includes enzyme replacement therapy (ERT) and pain management.
The Fabry Disease drugs in development market research report provide comprehensive information on the therapeutics under development for Fabry Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fabry Disease and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Fabry Disease | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 40 molecules, with 37 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Fabry Disease therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Fabry Disease pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Fabry Disease treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
4D Molecular Therapeutics IncAceLink Therapeutics Inc
Allife Medical Science and Technology Co Ltd
Amicus Therapeutics Inc
Bioasis Technologies Inc
Biosidus SA
BioStrategies LC
CANbridge Life Sciences Ltd
CellGenTech Inc
Chiesi Farmaceutici SpA
Eleva GmbH
Equaly SA
Freeline Therapeutics Holdings Plc
GC Biopharma Corp
Generium
Hanmi Pharmaceuticals Co Ltd
Idorsia Pharmaceutical Ltd
ISU ABXIS Co Ltd
KYORIN Pharmaceutical Co Ltd
Kyoto Prefectural University of Medicine
M6P Therapeutics
MOGAM Biotechnology Research Institute
Pfizer Inc
Pharming Group NV
Sangamo Therapeutics Inc
Sanofi
Sichuan Zhishan Weixin Biotechnology Co Ltd
Sigilon Therapeutics Inc
Spanish National Research Council
Takeda Pharmaceutical Co Ltd
UniQure NV
Walking Fish Therapeutics Inc
Yuhan Corp
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Fabry Disease reports